ULTRAGENYX PHARMACEUTICAL INC. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/e0ead587-78d8-4a93-8c7f-70264640ad1b/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-575.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-057329 |
| FY 2024 | $-569.0M | 2024-01-01 – 2024-12-31 | evidence 0001193125-26-057329 |
| FY 2023 | $-607.0M | 2023-01-01 – 2023-12-31 | evidence 0001193125-26-057329 |
| FY 2022 | $-707.4M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003096 |
| FY 2021 | $-454.0M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-001284 |
| FY 2020 | $-186.6M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-005610 |
| FY 2019 | $-402.7M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-004667 |
| FY 2018 | $-197.6M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003324 |
| FY 2017 | $-302.1M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-002535 |
| FY 2016 | $-245.9M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-001714 |
| FY 2015 | $-145.6M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-013430 |
| FY 2014 | $-59.8M | 2014-01-01 – 2014-12-31 | evidence 0001564590-15-002066 |
| FY 2013 | $-73.2M | 2010-04-22 – 2014-03-31 | evidence 0001564590-14-002047 |
| FY 2012 | $-16.3M | 2012-01-01 – 2012-12-31 | evidence 0001564590-15-002066 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
ULTRAGENYX PHARMACEUTICAL INC. — all facts · Revenue · Operating Income